Keyphrases
Luteinizing Hormone
100%
Monotherapy
100%
Androgen Blockade
100%
Androgen Deprivation Therapy
100%
No Significant Difference
28%
Quality of Life
28%
Patient Well-being
28%
Diarrhea
14%
Clinically Significant
14%
Confounding Effect
14%
Prostate Cancer
14%
Baseline Characteristics
14%
Therapy Groups
14%
Clinical Significance
14%
Quality of Life Assessment
14%
Pain Relief
14%
Newly Diagnosed
14%
Pain Score
14%
Randomized Clinical Trial
14%
Symptom Score
14%
Depression Score
14%
Domain Scores
14%
EORTC QLQ-C30
14%
Antiandrogen
14%
EORTC
14%
Leuprolide
14%
Bicalutamide
14%
Depression Questionnaires
14%
Medicine and Dentistry
Monotherapy
100%
Androgen
100%
Androgen Deprivation Therapy
100%
Gonadorelin Agonist
100%
Quality of Life
71%
Drug Therapy
14%
Clinical Significance
14%
Analgesia
14%
Randomized Clinical Trial
14%
Prostate Cancer
14%
Diarrhea
14%
Group Therapy
14%
Leuprorelin
14%
Bicalutamide
14%
Antiandrogen
14%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Androgen
100%
Gonadorelin Agonist
100%
Diarrhea
8%
Prostate Cancer
8%
Randomized Clinical Trial
8%
Leuprorelin
8%
Antiandrogen
8%
Bicalutamide
8%
Neuroscience
Androgen
100%
Gonadotropin-Releasing Hormone Agonist
100%
Group Therapy
8%
Leuprorelin
8%
Antiandrogen
8%
Bicalutamide
8%